Highlights

  • Arovella released two clinical batches of its ALA-101 cell therapy.
  • Two activated trial sites began screening eligible patients.
  • The company expected its first patient dosing during October 2026.
  • A post-quarter tax refund added AUD 4.03 million to available funding.

Arovella Therapeutics (ASX:ALA) develops donor-derived cell therapies for cancer, with ALA-101 targeting CD19-positive blood cancers. Its September 2026 quarterly update, released on 23 October, described the transition from manufacturing and trial start-up towards first human dosing. Clinical supply and initial sites were ready, but the report still presented patient dosing and early clinical data as milestones ahead.

Clinical Batches Reach Patient-Use Readiness

Two ALA-101 batches were manufactured and released for clinical use during September. The company stated that this supply was sufficient to complete dose escalation and begin dose expansion.

The product uses invariant natural killer T cells from healthy donors. Multiple doses can be manufactured in advance and stored, avoiding the need to produce a separate therapy from each trial participant's cells.

That manufacturing approach was intended to simplify treatment logistics. Patients still had to satisfy screening and other clinical requirements before receiving treatment, so ready-made supply did not remove the study's safety and eligibility procedures.

Screening Opens the First Trial Pathway

Two trial sites were active and screening patients at the reporting date. The first-in-human study would evaluate ALA-101 in relapsed or refractory CD19-positive non-Hodgkin lymphoma and certain leukaemias.

The trial combined dose escalation and expansion. Its objectives included assessing safety and tolerability, identifying an appropriate dose for further development and generating preliminary evidence of antitumour activity.

The company also planned to measure cell expansion, persistence and depletion of CD19-positive B cells. Those observations could inform later development in blood cancers and the investigation of possible autoimmune applications.

Observation Windows Set the Initial Pace

For the first three patients, regulators required 28 days between dosing to watch for adverse safety signals. A similar observation period would apply after the first patient at each higher dose level.

Screening could continue during those windows, allowing subsequent eligible patients to be prepared while safety observations were completed. The planned recruitment pace therefore depended on both screening and the trial's staggered early dosing requirements.

By the end of Q1CY27, the company expected to have completed dosing at the first level and started the second. Two more sites were being activated, with further expansion dependent on availability of initial safety information.

Solid-Tumour Research Runs Alongside the Trial

The ALA-105 program targeted CLDN18.2 using armoured CAR-iNKT cells. Animal studies were progressing, with results expected in the weeks following the report.

Supportive findings would help guide continued advancement towards clinical testing. At the announcement date, this remained a preclinical program rather than a treatment already evaluated in human patients.

The company also planned regulatory preparation for possible ALA-101 development in autoimmunity and non-clinical and manufacturing work to support ALA-105. These plans were distinct from the immediate priority of obtaining early ALA-101 safety and activity data in blood cancers.

Tax Refund Extends the Funding Position

Cash and equivalents were AUD 11.6 million on 30 September 2026, with net operating cash outflow of AUD 2.7 million during the quarter. Research, development and staff costs represented 89% of operating outflows.

In October, the company received an AUD 4.03 million FY26 research tax incentive rebate. Adding that receipt to September-end cash produced an approximately AUD 15.63 million pro-forma balance before other post-quarter cash movements.

The reported position therefore distinguished actual quarter-end cash from the illustrative balance after the refund. Initial dosing, observation periods and subsequent clinical results remained the next tests for the lead program.